US · 1 entry · 1 publication
Ultragenyx Pharmaceutical Inc.
More bullish than bearish among those that state a stance.
Free during launch: log in or sign up with your email to see it.
Sign up freeSubstack · Hated Moats · Hated Moats Investors
The first catalyst has already gone right. The second FDA decision and another pivotal readout create one of the most concentrated catalyst setups in biotech.
Since publication −36.2% α −36.1 pp vs S&P 500 · USD
Prices as of the Oct 27, 2026 close. Past performance does not guarantee future results. Price-only, excluding dividends, in local currency. Data may be delayed or inaccurate. Not investment advice. How it is calculated.